<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5015">
  <stage>Registered</stage>
  <submitdate>10/06/2015</submitdate>
  <approvaldate>10/06/2015</approvaldate>
  <nctid>NCT02470481</nctid>
  <trial_identification>
    <studytitle>A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics</studytitle>
    <scientifictitle>Psoriatic Arthritis In Skin Clinics (PARIS) Study. A Multicentre, Observational, Descriptive Cross-Cultural Validation Study and Estimate of the Proportion of Patients With Psoriatic Arthritis Among Psoriasis Patients Attending Dermatology Clinics Selected for This Study</scientifictitle>
    <utrn />
    <trialacronym>PARIS</trialacronym>
    <secondaryid>CNTO148PSA4001</secondaryid>
    <secondaryid>CR103908</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Psoriatic Arthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Rheumatoid arthritis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - No Intervention

Cohort 1 - Participants with psoriatic arthritis among psoriasis particiants attending dermatology clinics.


Other interventions: No Intervention
This is an obervational study

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of Participants With Psoriatic Arthritis - Percentage of participants with psoriatic arthritis will be assessed using formula: Number of participants diagnosed with psoriatic arthritis divided by total number of participants with psoriasis attending the dermatology clinic.</outcome>
      <timepoint>Baseline up to Day 28</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patient must be a man or woman aged 18 to 65 years of age, inclusive

          -  The patient must have an established diagnosis of psoriasis (based upon clinical
             evidence, and documented medical history [19])

          -  The patient must be able to read and write in the target language (English, Mandarin
             or Korean; or other relevant target languages)

          -  Each patient must sign an informed consent form (ICF) indicating that he or she
             understands the purpose of and procedures required for the study and are willing to
             participate in the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  An established diagnosis of psoriatic arthritis

          -  Ever have received systemic treatment with a disease modifying antirheumatic drug
             (DMARD) for arthritis or spondylitis (inflammatory back pain)

          -  Ever have received systemic treatment with a biologic therapy for psoriasis (including
             infliximab, golimumab, ustekinumab, adalimumab or etanercept)

          -  A history of employment in or are currently employed in the healthcare industry; or

          -  Participated in the translation and linguistic validation of the EARP questionnaire</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>250</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital> - Fitzroy</hospital>
    <hospital> - New Lambton</hospital>
    <postcode> - Fitzroy</postcode>
    <postcode> - New Lambton</postcode>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hangzhou</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Janssen Research &amp; Development, LLC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to conduct full psychometric testing of the Early Arthritis for
      Psoriatic Patients (EARP) questionnaire in Australian, Korean and Chinese populations</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02470481</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janssen Research &amp; Development, LLC Clinical Trial</name>
      <address>Janssen Research &amp; Development, LLC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>